Last reviewed · How we verify

NCT03854825: NEPAKI-CS

Neutral Endopeptidase for Early Detection of Acute Kidney Injury After Cardiac Surgery

Completed Last updated 22 April 2019
What this trial tests

trial testing Cardiac surgery in Acute Kidney Injury in 100 participants. Completed in 1 April 2019.

Timeline
30 October 2016
Primary endpoint
25 January 2018
1 April 2019

Quick facts

Lead sponsorMedical University of Vienna
StatusCompleted
Study typeOBSERVATIONAL
Enrollment100
Start date30 October 2016
Primary completion25 January 2018
Estimated completion1 April 2019
Sites1 location across Austria

Drugs / interventions tested

Conditions studied

Sponsor

Medical University of Vienna

Who can join

18 and older, any sex, with Acute Kidney Injury. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators want to investigate if the urinary biomarker neprilysin can identify cardiac surgical patients suffering from postoperative AKI within 24 hours.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Urinary neprilysin for early detection of acute kidney injury after cardiac surgery: A prospective observational study.
    Bernardi MH, Wagner L, Ryz S, Puchinger J, et al · · 2021 · cited 8× · PMID 32941200 · DOI 10.1097/eja.0000000000001321

Verify or expand the search:

Other trials of Cardiac surgery

Trials testing the same drug.

Other recruiting trials for Acute Kidney Injury

Currently open trials in the same condition.

Other Medical University of Vienna trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03854825.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing